Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials
published in: Critical Care Medicine
date of publication: 2003-01-01
language: English
main subject: phase IV clinical trial, sepsis, drotrecogin alfa
Cites articles
There is nothing here
Article - wd:Q35052434